Cetirizine hydrochloride 5 mg/5mL Solution, 473 mL — NDC 23155-929-52 (Billing 23155-0929-52)
This is a package of 473 mL of Cetirizine hydrochloride 5 mg/5mL Solution from Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc., marketed since Mar 2025 and currently FDA-listed; retail pharmacies pay about $0.3318 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 23155-929-52 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 23155 labeler · 929 product · 52 package
- Package marketed since
- Mar 1, 2025
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 473 mL per package
- Barcode (UPC)
- 0323155929515, 0323155929522
- Medicaid fills, this package
- 6,995 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Other active recalls for Cetirizine Hydrochloride (different manufacturers) — 3 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 021687
- GCN: 49290
- GPI-14 (Medi-Span): 41550020102010
- HICL (First Databank): 006544
- AHFS class code: 04:08.00.00
- RxCUI (RxNorm): 1014673
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Histamine-1 Receptor Antagonist class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Cetirizine is used to treat allergy symptoms: sneezing runny nose itching of the nose or throat red, itchy, or watery eyes Cetirizine is also used to treat urticaria (hives; itchy raised red bumps on skin). Cetirizine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. Cetirizine is also available in combination with pseudoephedrine. This monograph only includes information about the use of cetirizine alone. If you are taking the cetirizine and pseudoephedrine combination product, read th...
Read the full MedlinePlus article ↗- It relieves allergy symptoms. Over-the-counter versions ease runny nose, sneezing, itchy, watery eyes and an itchy nose or throat from hay fever. Specific products treat hives, yea...
- It can. Drowsiness was reported, and it was more common at higher doses in children. Be careful driving or using machinery until you know how it affects you, and avoid alcohol.
- The oral solution can be taken with or without food. Food slightly delays how fast it works but does not change how much your body absorbs.
- Check with me first if you take sedatives or tranquilizers, since they can add to drowsiness. The label found no significant interactions with azithromycin, pseudoephedrine, ketoco...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Cetirizine Hydrochloride — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.332 | $156.94 / 473 ml |
| Medicaid paysCMS SDUD · 12 mo | $0.1028 | $48.62 / 473 ml |
| Medicare drug plans payPart D · Q2 2026 | $0.0685 | $32.40 / 473 ml |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 23155-0929-51 23155-929-51 | 120 mL in 1 BOTTLE | — | — | 2025-03-01 | — | Active |
| 23155-0929-52 You're viewing this Main listing | 473 mL in 1 BOTTLE | $0.3318 / mL | $156.94 | 2025-03-01 | — | Active |
You're viewing the largest of 2 pack sizes for this product.
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 23155-0929-51?
What NDC number is used to bill for this package of Cetirizine hydrochloride 5 mg/5mL Solution?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Cetirizine Hydrochloride 1 mg/mL 00121-0874-04 | PAI | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride 1 mg/mL 16571-0134-12 | Rising | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride 1 mg/mL 45802-0626-26 | Padagis | 1 bottle | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride 1 mg/mL 51672-4070-08 | Sun | 1 bottle | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride Oral Solution 5 mg/5mL 62135-0057-41 | Chartwell | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride 1 mg/mL 69452-0426-55 | Bionpharma | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Cetirizine hydrochloride 1 mg/mL 72888-0480-01 | Advagen | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Cetirizine Hydrochloride Oral Solution 1 mg/mL 83745-0185-04 | APOZEAL | 120 ml | $0.022 | AA | Availability likely | save 93% |
| Good Neighbor Pharmacy Childrens All Day Allergy 5 mg/5mL 46122-0203-26 | Amerisource | 1 bottle | $0.035 | — | Availability likely | save 89% |
| Cetirizine Hydrochloride 1 mg/mL 57237-0357-12 | Rising | 120 ml | $0.035 | — | Availability likely | save 89% |
| Cetirizine Hydrochloride 1 mg/mL 57237-0358-12 | Rising | 120 ml | $0.035 | — | Availability likely | save 89% |
| foster and thrive childrens allergy relief 5 mg/5mL 70677-1042-01 | Strategic | 1 bottle | $0.035 | — | Availability likely | save 89% |
| Cetirizine Hydrochloride 1 mg/mL 70677-1236-01 | STRATEGIC | 1 bottle | $0.035 | — | Availability likely | save 89% |
| Childrens Allergy Relief 1 mg/mL 70677-0149-01 | Strategic | 1 bottle | $0.037 | — | FDA listed | save 89% |
| Good Sense Childrens All Day Allergy 5 mg/5mL 00113-0189-26 | L. | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Good Sense Childrens All Day Allergy 5 mg/5mL 00113-0503-26 | L. | 1 bottle | $0.038 | — | Availability likely | save 89% |
| childrens cetirizine hydrochloride 5 mg/5mL 00904-6765-20 | Major | 1 bottle | $0.038 | — | Availability likely | save 89% |
| cetirizine hydrochloride 5 mg/5mL 45802-0974-26 | Padagis | 1 bottle | $0.038 | — | Availability likely | save 89% |
| All Day Allergy 5 mg/5mL 46122-0101-26 | Amerisource | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Childrens Allergy Relief 1 mg/mL 69230-0316-11 | Camber | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Leader Childrens All Day Allergy 5 mg/5mL 70000-0214-01 | Cardinal | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Leader Childrens all day allergy 5 mg/5mL 70000-0215-01 | Cardinal | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Cetirizine Hydrochloride 1 mg/mL 70752-0104-06 | QUAGEN | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Cetrizine Hydrochloride 1 mg/mL 83745-0188-04 | APOZEAL | 1 bottle | $0.038 | — | Availability likely | save 89% |
| Cetirizine hydrochloride 5 mg/5mLthis 23155-0929-52 | Heritage | 473 ml | $0.332 | AA | Availability likely | — |
| Dye Free Childrens Cetirizine Hydrocholride 5 mg/5mL 68094-0004-62 | Precision | 10 cups | $0.447 | — | Availability likely | +35% |
| Wal-Zyr All Day Allergy 5 mg/5mL 00363-2106-01 | WALGREEN | 1 bottle | — | — | FDA listed | — |
| childrens allergy relief 5 mg/5mL 00363-3311-26 | Walgreen | 1 bottle | — | — | FDA listed | — |
| childrens allergy relief 5 mg/5mL 00363-3393-26 | Walgreen | 1 bottle | — | — | FDA listed | — |
| childrens allergy relief 5 mg/5mL 11822-0475-00 | Rite | 1 bottle | — | — | FDA listed | — |
| childrens allergy relief 5 mg/5mL 11822-1189-00 | Rite | 1 bottle | — | — | FDA listed | — |
| Rite Aid childrens allergy relief 1 mg/mL 11822-2106-08 | Rite | 1 bottle | — | — | FDA listed | — |
| childrens cetirizine hydrochloride 5 mg/5mL 17856-6765-01 | ATLANTIC | 72 cups | — | — | FDA listed | — |
| Signature Care Childrens Allergy Relief 5 mg/5mL 21130-0189-34 | Safeway | 1 bottle | — | — | Discontinued | — |
| childrens allergy relief 5 mg/5mL 21130-0465-34 | Safeway | 1 bottle | — | — | FDA listed | — |
| Signature Care Childrens Allergy Relief 5 mg/5mL 21130-0475-26 | Safeway | 1 bottle | — | — | Discontinued | — |
| childrens allergy relief 5 mg/5mL 21130-0653-26 | Safeway | 1 bottle | — | — | FDA listed | — |
| childrens all day allergy 5 mg/5mL 30142-0189-26 | Kroger | 1 bottle | — | — | FDA listed | — |
| Childrens All Day Allergy 5 mg/5mL 30142-0475-26 | Kroger | 1 bottle | — | — | FDA listed | — |
| childrens dye free allergy relief 5 mg/5mL 30142-0643-26 | Kroger | 1 bottle | — | — | FDA listed | — |
| childrens dye free allergy relief 5 mg/5mL 30142-0689-26 | Kroger | 1 bottle | — | — | FDA listed | — |
| Topcare Childrens All Day Allergy 5 mg/5mL 36800-0189-26 | Topco | 1 bottle | — | — | FDA listed | — |
| TopCare Childrens All Day Allergy 5 mg/5mL 36800-0475-00 | Topco | 1 bottle | — | — | FDA listed | — |
| HEB Allergy Relief 5 mg/5mL 37808-0102-08 | H | 1 bottle | — | — | FDA listed | — |
| Allergy Relief 1 mg/mL 37808-0106-08 | H | 1 bottle | — | — | FDA listed | — |
| childrens allergy relief 5 mg/5mL 37808-0671-26 | H | 1 bottle | — | — | Discontinued | — |
| Equaline childrens all day allergy 5 mg/5mL 41163-0475-26 | United | 1 bottle | — | — | FDA listed | — |
| Childrens 24 Hour Allergy 5 mg/5mL 41250-0189-26 | Meijer | 1 bottle | — | — | FDA listed | — |
| Childrens 24 Hour Allergy 5 mg/5mL 41250-0475-26 | Meijer | 1 bottle | — | — | FDA listed | — |
| careone childrens allergy relief 5 mg/5mL 41520-0301-26 | American | 1 bottle | — | — | FDA listed | — |
| careone childrens allergy relief 5 mg/5mL 41520-0902-26 | American | 1 bottle | — | — | FDA listed | — |
| Childrens All Day Allergy 5 mg/5mL 42507-0203-26 | HyVee | 1 bottle | — | — | FDA listed | — |
| childrens all day allergy 5 mg/5mL 42507-0475-26 | HyVee | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy Relief 5 mg/5mL 49035-0106-08 | Wal-Mart | 1 bottle | — | — | FDA listed | — |
| Equate Childrens Allergy Relief 5 mg/5mL 49035-0276-01 | Wal-Mart | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Sugar Free Grape 1 mg/mL 50090-1103-00 | A-S | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy Relief 1 mg/mL 50090-4741-00 | A-S | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 50090-5220-00 | A-S | 1 bottle | — | AA | FDA listed | — |
| Good Sense Childrens All Day Allergy 5 mg/5mL 50090-7068-00 | A-S | 1 bottle | — | — | FDA listed | — |
| Zyrtec Hives 1 mg/mL 50580-0128-04 | Kenvue | 1 bottle | — | — | FDA listed | — |
| Childrens Zyrtec Allergy 5 mg/5mL 50580-0721-05 | Kenvue | 1 bottle | — | — | FDA listed | — |
| Childrens Zyrtec 5 mg/5mL 50580-0730-01 | Kenvue | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Sugar Free Grape 1 mg/mL 51672-2102-01 | Sun | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 51672-2106-01 | Sun | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride 1 mg/mL 51672-2147-01 | Sun | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy Relief 1 mg/mL 55315-0354-31 | Fred's, | 1 bottle | — | — | FDA listed | — |
| DG Health Childrens All Day Allergy 5 mg/5mL 55910-0714-26 | Dolgencorp, | 1 bottle | — | — | FDA listed | — |
| childrens allergy 5 mg/5mL 56062-0102-08 | Publix | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy 1 mg/mL 56062-0106-08 | Publix | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Allergy 1 mg/mL 58602-0028-20 | Aurohealth | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Hives Relief 1 mg/mL 58602-0030-20 | Aurohealth | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Hives Relief 1 mg/mL 58602-0036-15 | Aurohealth | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy Relief 1 mg/mL 58602-0422-12 | Aurohealth | 1 bottle | — | — | FDA listed | — |
| Childrens Allergy Relief 5 mg/5mL 59779-0509-26 | CVS | 1 bottle | — | — | FDA listed | — |
| allergy relief childrens 5 mg/5mL 59779-0837-26 | CVS | 1 bottle | — | — | FDA listed | — |
| Allergy Relief Childrens 5 mg/5mL 59779-0884-26 | CVS | 1 bottle | — | — | Discontinued | — |
| Cetirizine Hydrochloride 1 mg/mL 61037-0479-02 | BAJAJ | 120 ml | — | AA | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 61037-0480-22 | BAJAJ | 120 ml | — | — | FDA listed | — |
| Childrens Allergy Relief 1 mg/mL 63868-0865-04 | C.D.M.A., | 1 bottle | — | — | FDA listed | — |
| Kirkland Signature Childrens Aller Tec 5 mg/5mL 63981-0475-43 | Costco | 2 bottles | — | — | FDA listed | — |
| Welby Childrens Allergy Relief 5 mg/5mL 64024-0475-26 | Aldi | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 5 mg/5mL 65162-0003-86 | Amneal | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 5 mg/5mL 65162-0005-86 | Amneal | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 5 mg/5mL 65162-0684-86 | Amneal | 118 ml | — | AA | FDA listed | — |
| Childrens Cetirizine Hydrochloride 5 mg/5mL 68016-0023-43 | Chain | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirzine 5 mg/5mL 68016-0106-08 | Pharmacy | 1 bottle | — | — | FDA listed | — |
| Premier Value Childrens Cetirizine 5 mg/5mL 68016-0165-00 | Pharmacy | 1 bottle | — | — | FDA listed | — |
| SIMPLY RIGHT childrens cetirizine 5 mg/5mL 68196-0102-01 | Sam's | 2 bottles | — | — | Discontinued | — |
| Members Mark Childrens Cetirizine 5 mg/5mL 68196-0475-43 | Sam's | 2 bottles | — | — | FDA listed | — |
| Good Sense Childrens All Day Allergy 5 mg/5mL 68788-4093-01 | Preferred | 1 bottle | — | — | FDA listed | — |
| childrens cetirizine hydrochloride 5 mg/5mL 68788-8188-01 | Preferred | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 68788-8282-01 | Preferred | 1 bottle | — | AA | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 68788-8523-01 | Preferred | 1 bottle | — | AA | FDA listed | — |
| Good Sense Childrens All Day Allergy 5 mg/5mL 68788-8803-01 | Preferred | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride Oral Solution 1 mg/mL 68788-8890-01 | Preferred | 120 ml | — | AA | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 69206-0990-01 | Aventura | 120 ml | — | AA | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 70752-0103-06 | QUAGEN | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 71205-0435-04 | Proficient | 1 bottle | — | AA | FDA listed | — |
| Childrens Cetirizine Hydrochloride Sugar Free Grape 1 mg/mL 71205-0705-72 | Proficient | 1 bottle | — | — | FDA listed | — |
| childrens cetirizine hydrochloride 5 mg/5mL 71205-0722-04 | Proficient | 1 bottle | — | — | FDA listed | — |
| Cetirizine Hydrochloride 1 mg/mL 72162-2073-02 | Bryant | 1 bottle | — | — | FDA listed | — |
| cetirizine hydrochloride 5 mg/5mL 72162-2339-02 | Bryant | 1 bottle | — | — | FDA listed | — |
| Basic Care Childrens All Day Allergy 5 mg/5mL 72288-0330-34 | Amazon.com | 1 bottle | — | — | FDA listed | — |
| basic care childrens all day allergy 5 mg/5mL 72288-0475-34 | Amazon.com | 1 bottle | — | — | FDA listed | — |
| up and up childrens allergy 5 mg/5mL 82442-0475-26 | Target | 1 bottle | — | — | FDA listed | — |
| up and up childrens allergy 5 mg/5mL 82442-0617-26 | Target | 1 bottle | — | — | FDA listed | — |
| Childrens Cetirizine Hydrochloride Sugar Free Grape 1 mg/mL 83939-0009-01 | VERITYRX, | 5 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Cetirizine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII Q40Q9N063P
Acetic acid is a weak organic acid commonly used in medicines as a buffer and pH adjuster. It helps maintain the proper acidity level to ensure the drug remains stable and effective in its formulation.
-
UNII Y882YXF34X
Calcium acetate is a mineral salt made from calcium and acetic acid. In medicines, it acts as a binder to hold ingredients together and can help control the acidity level of the formulation.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII Z8IX2SC1OH
Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 5, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuti... labeler code 23155
- Amlodipine and Benazepril Hydrochloride 5 mg; 20 mg Capsule NDC 23155-922-01
- Amlodipine and Benazepril Hydrochloride 5 mg; 40 mg Capsule NDC 23155-923-01
- Amlodipine and Benazepril Hydrochloride 10 mg; 20 mg Capsule NDC 23155-924-01
- Amlodipine and Benazepril Hydrochloride 10 mg; 40 mg Capsule NDC 23155-925-01
- Hydrocortisone 100 mg/60mL Suspension NDC 23155-926-51
- Prednisolone 15 mg/5mL Solution NDC 23155-927-51
- Thiamine Hydrochloride 100 mg/mL Injection, Solution NDC 23155-933-41
- Bethanechol Chloride 5 mg Tablet NDC 23155-934-01
- Bethanechol Chloride 10 mg Tablet NDC 23155-935-01
- Bethanechol Chloride 25 mg Tablet NDC 23155-936-01
- Bethanechol Chloride 50 mg Tablet NDC 23155-937-01
- Tetrabenazine 12.5 mg Tablet NDC 23155-938-63
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Perennial Allergic Rhinitis: Cetirizine hydrochloride oral solution is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. Chronic Urticaria: Cetirizine hydrochloride oral solution is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age.
It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Cetirizine hydrochloride oral solution can be taken without regard to food consumption. Children 2 to 5 Years for Chronic Urticaria: The recommended initial dose of cetirizine hydrochloride oral solution in children aged 2 to 5 years is 2.5 mg (½ teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoonful syrup once a day, or ½ teaspoonful syrup given every 12 hours.
Children 6 months to <2 years for Perennial Allergic Rhinitis and Chronic Urticaria: The recommended dose of cetirizine hydrochloride oral solution in children 6 months to 23 months of age is 2.5 mg (½ teaspoonful) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ½ teaspoonful (2.5 mg) every 12 hours.
⛔ Contraindications ▾
CONTRAINDICATIONS Cetirizine hydrochloride is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Pediatric studies were conducted with cetirizine hydrochloride. More than 1300 pediatric patients aged 6 to 11 years with more than 900 treated with cetirizine hydrochloride at doses of 1.25 to 10 mg per day were included in controlled and uncontrolled clinical trials conducted in the United States. The duration of treatment ranged from 2 to 12 weeks.
Placebo-controlled trials up to 4 weeks duration included 168 pediatric patients aged 2 to 5 years who received cetirizine, the majority of whom received single daily doses of 5 mg. A placebo-controlled trial 18 months in duration included 399 patients aged 12 to 24 months treated with cetirizine (0.25 mg/kg bid), and another placebo-controlled trial of 7 days duration included 42 patients aged 6 to 11 months who were treated with cetirizine (0.25 mg/kg bid). The majority of adverse reactions reported in pediatric patients aged 2 to 11 years with cetirizine hydrochloride were mild or moderate.
In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in pediatric patients receiving up to 10 mg of cetirizine hydrochloride was uncommon (0.4% on cetirizine hydrochloride vs. 1.0% on placebo). Table 1 lists adverse experiences which were reported for cetirizine hydrochloride 5 and 10 mg in pediatric patients aged 6 to 11 years in placebo-controlled clinical trials in the United States and were more common with cetirizine hydrochloride than placebo.
Of these, abdominal pain was considered treatment-related and somnolence appeared to be dose-related, 1.3% in placebo, 1.9% at 5 mg and 4.2% at 10 mg. The adverse experiences reported in pediatric patients aged 2 to 5 years in placebo-controlled trials were qualitatively similar in nature and generally similar in frequency to those reported in trials with children aged 6 to 11 years. In the placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences, were similar in the cetirizine and placebo treatment groups in each study.
Somnolence occurred with essentially the same frequency in patients who received cetirizine and patients who received placebo. In a study of 1 week duration in children 6 to 11 months of age, patients who received cetirizine exhibited greater irritability/fussiness than patients on placebo. In a study of 18 months duration in patients 12 months and older, insomnia occurred more frequently in patients who received cetirizine compared to patients who received placebo (9.0% v.
5.3%). In those patients who received 5 mg or more per day of cetirizine as compared to patients who received placebo, fatigue (3.6% v. 1.3%) and malaise (3.6% v.
1.8%) occurred more frequently. Table 1 Adverse Experiences Reported in Pediatric Patients Aged 6 to 11 Years in Placebo- Controlled United States Cetirizine Hydrochloride Trials (5 or 10 mg Dose) Which Occurred at a Frequency of ≥ 2% in Either the 5-mg or the 10-mg Cetirizine Hydrochloride Group, and More Frequently Than in the Placebo Group Adverse Experiences Placebo (N=309) Cetirizine hydrochloride 5 mg (N=161) 10 mg (N=215) Headache 12.3% 11.0% 14.0% Pharyngitis 2.9% 6.2% 2.8% Abdominal pain 1.9% 4.4% 5.6% Coughing 3.9% 4.4% 2.8% Somnolence 1.3% 1.9% 4.2% Diarrhea 1.3% 3.1% 1.9% Epistaxis 2.9% 3.7% 1.9% Bronchospasm 1.9% 3.1% 1.9% Nausea 1.9% 1.9% 2.8% Vomiting 1.0% 2.5% 2.3% The following events were observed infrequently (less than 2%), in either 3982 adults and children 12 years and older or in 659 pediatric patients aged 6 to 11 years who received cetirizine hydrochloride in U.S. trials, including an open adult study of six months duration.
A causal relationship of these infrequent events with cetirizine hydrochloride administration has not been established. Autonomic Nervous System: anorexia, flushing, increased salivation, urinary retention. Cardiovascular: cardiac failure, hypertension, palpitation, tachycardia.
Central and Peripheral Nervous Systems: abnormal coordination, ataxia, c… [Excerpted — this section continues on DailyMed.]
🆘 Overdosage ▾
OVERDOSAGE Overdosage has been reported with cetirizine hydrochloride. In one adult patient who took 150 mg of cetirizine hydrochloride, the patient was somnolent but did not display any other clinical signs or abnormal blood chemistry or hematology results. In an 18 month old pediatric patient who took an overdose of cetirizine hydrochloride (approximately 180 mg), restlessness and irritability were observed initially; this was followed by drowsiness.
Should overdose occur, treatment should be symptomatic or supportive, taking into account any concomitantly ingested medications. There is no known specific antidote to cetirizine hydrochloride. Cetirizine hydrochloride is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.
The acute minimal lethal oral doses were 237 mg/kg in mice (approximately 95 times the maximum recommended daily oral dose in adults on a mg/m 2 basis, or approximately 40 times the maximum recommended daily oral dose in infants on a mg/m 2 basis) and 562 mg/kg in rats (approximately 460 times the maximum recommended daily oral dose in adults on a mg/m 2 basis, or approximately 190 times the maximum recommended daily oral dose in infants on a mg/m 2 basis). In rodents, the target of acute toxicity was the central nervous system, and the target of multiple-dose toxicity was the liver.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Mechanism of Actions: Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H 1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity.
In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H 1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain.
Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H 1 receptors. Pharmacokinetics: Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (T max ) of approximately 1 hour following oral administration of tablets or syrup in adults. Comparable bioavailability was found between the tablet and syrup dosage forms.
When healthy volunteers were administered multiple doses of cetirizine (10 mg tablets once daily for 10 days), a mean peak plasma concentration (C max ) of 311 ng/mL was observed. No accumulation was observed. Cetirizine pharmacokinetics were linear for oral doses ranging from 5 to 60 mg.
Food had no effect on the extent of cetirizine exposure (AUC) but T max was delayed by 1.7 hours and C max was decreased by 23% in the presence of food. Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 25 to 1000 ng/mL, which includes the therapeutic plasma levels observed. Metabolism: A mass balance study in 6 healthy male volunteers indicated that 70% of the administered radioactivity was recovered in the urine and 10% in the feces.
Approximately 50% of the radioactivity was identified in the urine as unchanged drug. Most of the rapid increase in peak plasma radioactivity was associated with parent drug, suggesting a low degree of first-pass metabolism. Cetirizine is metabolized to a limited extent by oxidative O-dealkylation to a metabolite with negligible antihistaminic activity.
The enzyme or enzymes responsible for this metabolism have not been identified. Elimination: The mean elimination half-life in 146 healthy volunteers across multiple pharmacokinetic studies was 8.3 hours and the apparent total body clearance for cetirizine was approximately 53 mL/min. Interaction Studies Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
No interactions were observed. In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed. The disposition of theophylline was not altered by concomitant cetirizine administration.
Special Populations Pediatric Patients: In pediatric patients aged 2 to 5 years who received 5 mg of cetirizine, the mean C max was 660 ng/mL. Based on cross study comparisons, the weight normalized, apparent total body clearance was 81 to 111% greater and the elimination half life was 33 to 41% shorter in the pediatric population than in adults. In pediatric patients aged 6 to 23 months who received a single dose of 0.25 mg/kg cetirizine oral solution (mean dose 2.3 mg), the mean C max was 390 ng/mL.
Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 304% greater and the elimination half-life was 63% shorter in this pediatric population compared to adults. The average AUC(0-t) in children 6 months to <2 years of age receiving the maximum dose of cetirizine solution (2.5 mg twice a day) is expected to be two-fold higher than that observed in adults receiving a dose of 10 mg cetirizine tablets once a day.… [Excerpted — this section continues on DailyMed.]
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Cetirizine Hydrochloride Oral Solution, USP is colorless to slightly yellow and available in grape flavor. Each teaspoon (5 mL) contains 5 mg cetirizine hydrochloride. Cetirizine Hydrochloride Oral Solution, USP is supplied as follows: NDC 23155-929-51(Grape Flavor) 120 mL bottles NDC 23155-929-52 (Grape Flavor) 473 mL bottles STORAGE: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000511US01 Revised: 01/2025 Avet logo
📋 Description ▾
DESCRIPTION Cetirizine hydrochloride is an orally active and selective H1-receptor antagonist. The chemical name is (±) - [2-[4-[(4-chlorophenyl)phenylmethyl] -1-piperazinyl] ethoxy] acetic acid, dihydrochloride. Cetirizine hydrochloride is a racemic compound with an empirical formula of C21H25ClN2O3•2HCl.
The molecular weight is 461.82 and the chemical structure is shown below: Cetirizine hydrochloride is a white, crystalline powder and is water soluble. Cetirizine hydrochloride oral solution is a colorless to slightly yellow syrup containing cetirizine hydrochloride at a concentration of 1 mg/mL (5 mg/5 mL) for oral administration. The pH is between 4 and 5.
The inactive ingredients of the syrup are: Cetirizine Hydrochloride Oral Solution, USP - Grape Flavor: calcium acetate; glacial acetic acid; glycerin; grape flavor; methylparaben; propylene glycol; propylparaben; and water. image description
⚠️ Precautions ▾
PRECAUTIONS Activities Requiring Mental Alertness: In clinical trials, the occurrence of somnolence has been reported in some patients taking cetirizine hydrochloride; due caution should therefore be exercised when driving a car or operating potentially dangerous machinery. Concurrent use of cetirizine hydrochloride with alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur. Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect. Carcinogenesis, Mutagenesis and Impairment of Fertility: In a 2-year carcinogenicity study in rats, cetirizine was not carcinogenic at dietary doses up to 20 mg/kg (approximately 15 times the maximum recommended daily oral dose in adults on a mg/m 2 basis, or approximately 7 times the maximum recommended daily oral dose in infants on a mg/m 2 basis).
In a 2-year carcinogenicity study in mice, cetirizine caused an increased incidence of benign liver tumors in males at a dietary dose of 16 mg/kg (approximately 6 times the maximum recommended daily oral dose in adults on a mg/m 2 basis, or approximately 3 times the maximum recommended daily oral dose in infants on a mg/m 2 basis). No increase in the incidence of liver tumors was observed in mice at a dietary dose of 4 mg/kg (approximately 2 times the maximum recommended daily oral dose in adults on a mg/m 2 basis, or approximately equivalent to the maximum recommended daily oral dose in infants on a mg/m 2 basis).
The clinical significance of these findings during long-term use of cetirizine hydrochloride is not known. Cetirizine was not mutagenic in the Ames test, and not clastogenic in the human lymphocyte assay, the mouse lymphoma assay, and in vivo micronucleus test in rats. In a fertility and general reproductive performance study in mice, cetirizine did not impair fertility at an oral dose of 64 mg/kg (approximately 25 times the maximum recommended daily oral dose in adults on a mg/m 2 basis).
Pediatric Use: The safety of cetirizine hydrochloride has been demonstrated in pediatric patients aged 6 months to 5 years. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl.
The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of cetirizine hydrochloride oral solution has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day.
The effectiveness of cetirizine hydrochloride for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 5 years is based on an extrapolation of the demonstrated efficacy of cetirizine hydrochloride in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis because this disease is thought to occur down to these ages in children.
The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than… [Excerpted — this section continues on DailyMed.]
🔒 Drug Abuse and Dependence ▾
DRUG ABUSE AND DEPENDENCE There is no information to indicate that abuse or dependency occurs with cetirizine hydrochloride.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 23155- 929 -51 Cetirizine Hydrochloride Oral Solution, USP 1 mg/mL Grape Flavor FOR ORAL USE ONLY 120 mL Rx only label-120mL
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL-LABEL-473 mL NDC 23155- 929 -52 Cetirizine Hydrochloride Oral Solution, USP 1 mg/mL Grape Flavor FOR ORAL USE ONLY 473 mL Rx only label-473mL